Cyberattacks against accounting software firm Wolters Kluwer and the City of Baltimore in May showed how the newest wave of malicious hacking can have significant, often...Technologyread more
The European parliamentary election is the second largest democratic exercise in the world.Europe Newsread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
Microsoft shares have gained 133% since November 2015, outperforming a tech "basket of unicorns" over that stretch.Technologyread more
The president's state visit comes amid tensions with carmaker Toyota over potential auto tariffs. Trump has repeatedly threatened Japanese and European carmakers with tariffs.Traderead more
The IRS is about to release a new draft of Form W-4, which will more closely reflect the changes stemming from the Tax Cuts and Jobs Act. For workers, that means they'll need...Personal Financeread more
The Mega Millions jackpot has spilled over $400 million. It would be the ninth largest winning since the game began in 2002.Personal Financeread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
When commercial real estate investor Manny Khoshbin spent $2.2 million on the fastest production car in the world, he had no idea it would very quickly also become the...Autosread more
Shares of Alexion fell Tuesday after the biopharmaceutical company said it missed its goal in a late-stage trial of the drug Solaris.
The stock ended the day down nearly 11 percent after the announcement, and has fallen more than 27 percent this year.
Alexion's drug Solaris is being studied as a treatment for a neuromuscular disease called Myasthenia Gravis, or MG, which causes patients to suffer muscle weakness that makes it difficult or impossible to perform daily activities like walking, talking, swallowing and breathing normally.
The study did not show a "statistical significance" from the baseline after week 26 of the trial, the company said. While it missed the primary goal, the study did hit targets on some secondary endpoints.
"While the REGAIN study missed its primary endpoint, I am encouraged by the clinically meaningful improvements in MG-ADL and QMG measures in patients treated with eculizumab compared with placebo," said Dr. James F. Howard Jr., distinguished professor of neuromuscular disease at the University of North Carolina School of Medicine. "There is an urgent need in the MG community for a therapy with the potential to dramatically improve the lives of patients with refractory MG, who continue to experience profound complement-mediated muscle weakness that makes it difficult or impossible to perform simple daily activities."
Alexion, which makes therapeutic products for patients with severe and ultra-rare disorders, will continue to analyze data from the study and will present results in July, during the International Congress on Neuromuscular Diseases in Toronto, the company said.
Analysts at Leerink Partners, an investment bank specializing in healthcare, reduced their Alexion price target from $210 to a $200 a share but maintained their "outperform" rating. Despite the recent results, they said the overwhelming evidence suggests that the drug is safe and benefits patients.
"The treatment has been endorsed by patients and the qualitative primary endpoint (imposed by regulators) is unlikely to be viewed as the 'be all and end all' in this trial, given the many other measures of benefit," Leerink said in a note published Tuesday. "Alexion's stock is likely to weaken on this announcement, but we would recommend buying especially if there is more than a mid-single digit sell-off."
Shares of Alexion traded below $139 a share Tuesday, down from their 52-week high of $208.88. The stock is down nearly 14 percent year over year.